Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates

Journal of Evolutionary Biology

Volumn 29, Issue 1, 2016, Pages 188-198

  Friman, V P ^a,b   Soanes Brown, D ^a   Sierocinski, P ^a   Molin, S ^c   Johansen, H K ^c,d   Merabishvili, M ^e,f,g   Pirnay, J P ^e   De Vos, D ^e   Buckling, A ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d University of Copenhagen   (Denmark)

^e QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^f George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

^g GHENT UNIVERSITY   (Belgium)

Author keywords

Antagonism; Experimental evolution; Host parasite interaction; Pathogenesis; Phage therapy

Indexed keywords

ANTAGONISM; ANTIBIOTIC RESISTANCE; BACTERIOPHAGE; BACTERIUM; COEVOLUTION; DISEASE TREATMENT; EXPERIMENT; HOST-PARASITE INTERACTION; PATHOGEN;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

ADAPTATION; CYSTIC FIBROSIS; EVOLUTION; HOST PATHOGEN INTERACTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; VIROLOGY;

ADAPTATION, BIOLOGICAL; BIOLOGICAL EVOLUTION; CYSTIC FIBROSIS; HOST-PATHOGEN INTERACTIONS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGES;

EID: 84953347618     PISSN: 1010061X     EISSN: 14209101     Source Type: Journal    
DOI: 10.1111/jeb.12774     Document Type: Article

References (72)

1. Abedon, S.T., Kuhl, S.J., Blasdel, B.G. & Kutter, E.M. 2011. Phage treatment of human infections. Bacteriophage 1: 66-85.
2. Addy, H.S., Askora, A., Kawasaki, T., Fujie, M. & Yamada, T. 2012. Loss of virulence of the phytopathogen Ralstonia solanacearum through infection by phiRSM filamentous phages. Phytopathology 102: 469-477.
3. Andersson, D.I. & Hughes, D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat. Rev. Microbiol. 8: 260-271.
4. Ashby, B., Gupta, S. & Buckling, A. 2014. Effects of epistasis on infectivity range during host-parasite coevolution. Evolution 68: 2972-2982.
5. Betts, A., Vasse, M., Kaltz, O. & Hochberg, M.E. 2013. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol. Appl. 6: 1054-1063.
6. Betts, A., Kaltz, O. & Hochberg, M.E. 2014. Contrasted coevolutionary dynamics between a bacterial pathogen and its bacteriophages. Proc. Natl. Acad. Sci. USA 111: 11109-11114.
7. Bruttin, A. & Brussow, H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49: 2874-2878.
8. Buckling, A. & Brockhurst, M. 2012. Bacteria-virus coevolution. Adv. Exp. Med. Biol. 751: 347-370.
9. Buckling, A. & Rainey, P.B. 2002. Antagonistic coevolution between a bacterium and a bacteriophage. Proc. Biol. Sci. 269: 931-936.
10. Burns, J.L., Gibson, R.L., McNamara, S., Yim, D., Emerson, J., Rosenfeld, M. et al. 2001. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J. Infect. Dis. 183: 444-452.
11. Burrowes, B., Harper, D.R., Anderson, J., McConville, M. & Enright, M.C. 2011. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev. Anti. Infect. Ther. 9: 775-785.
12. Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P. et al. 2011. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9: 894-896.
13. Ceyssens, P.J., Glonti, T., Kropinski, N.M., Lavigne, R., Chanishvili, N., Kulakov, L. et al. 2011. Phenotypic and genotypic variations within a single bacteriophage species. Virol. J. 8: 134.
14. Cotter, P.D., Ross, R.P. & Hill, C. 2013. Bacteriocins - a viable alternative to antibiotics? Nat. Rev. Microbiol. 11: 95-105.
15. Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O. et al. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201: 1096-1104.
16. Essoh, C., Blouin, Y., Loukou, G., Cablanmian, A., Lathro, S., Kutter, E. et al. 2013. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE 8: e60575.
17. Folkesson, A., Jelsbak, L., Yang, L., Johansen, H.K., Ciofu, O., Hoiby, N. et al. 2012. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective. Nat. Rev. Microbiol. 10: 841-851.
18. Friman, V.P. & Buckling, A. 2013. Effects of predation on real-time host-parasite coevolutionary dynamics. Ecol. Lett. 16: 39-46.
19. Friman, V.P., Hiltunen, T., Jalasvuori, M., Lindstedt, C., Laanto, E., Ormala, A.M. et al. 2011. High temperature and bacteriophages can indirectly select for bacterial pathogenicity in environmental reservoirs. PLoS ONE 6: e17651.
20. Friman, V.-P., Ghoul, M., Molin, S., Johansen, H.K. & Buckling, A. 2013. Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. PLoS ONE 8: e75380.
21. Gu, J., Liu, X., Li, Y., Han, W., Lei, L., Yang, Y. et al. 2012. A method for generation phage cocktail with great therapeutic potential. PLoS ONE 7: e31698.
22. Hall, A.R., Scanlan, P.D. & Buckling, A. 2011a. Bacteria-phage coevolution and the emergence of generalist pathogens. Am. Nat. 177: 44-53.
23. Hall, A.R., Scanlan, P.D., Morgan, A.D. & Buckling, A. 2011b. Host-parasite coevolutionary arms races give way to fluctuating selection. Ecol. Lett. 14: 635-642.
24. Hall, A.R., De Vos, D., Friman, V.P., Pirnay, J.P. & Buckling, A. 2012. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 78: 5646-5652.
25. Hansen, S.K., Rau, M.H., Johansen, H.K., Ciofu, O., Jelsbak, L., Yang, L. et al. 2012. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J. 6: 31-45.
26. Harrison, F. 2007. Microbial ecology of the cystic fibrosis lung. Microbiology 153: 917-923.
27. Hoe, S., Semler, D.D., Goudie, A.D., Lynch, K.H., Matinkhoo, S., Finlay, W.H. et al. 2013. Respirable bacteriophages for the treatment of bacterial lung infections. J. Aerosol. Med. Pulm. Drug Deliv. 26: 317-335.
28. Holder, K.K. & Bull, J.J. 2001. Profiles of adaptation in two similar viruses. Genetics 159: 1393-1404.
29. Jelsbak, L., Johansen, H.K., Frost, A.L., Thogersen, R., Thomsen, L.E., Ciofu, O. et al. 2007. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. Immun. 75: 2214-2224.
30. Johansen, H.K., Norregaard, L., Gotzsche, P.C., Pressler, T., Koch, C. & Hoiby, N. 2004. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?-A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr. Pulmonol. 37: 427-432.
31. Khawaldeh, A., Morales, S., Dillon, B., Alavidze, Z., Ginn, A.N., Thomas, L. et al. 2011. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 60: 1697-1700.
32. Kole, R., Krainer, A.R. & Altman, S. 2012. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discovery 11: 125-140.
33. Kutter, E. & Sulakvelidze, A. 2004. Bacteriophages: Biology and Applications. CRC Press, Boca Raton, FL.
34. Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S. et al. 2010. Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11: 69-86.
35. Krylov, V., Shaburova, O., Krylov, S. & Pleteneva, E. 2013. A genetic approach to the development of new therapeutic phages to fight pseudomonas aeruginosa in wound infections. Viruses 5: 15-53. [Correction added on 1 December after first online publication: Reference has been added].
36. Labrie, S.J., Samson, J.E. & Moineau, S. 2010. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8: 317-327.
37. Lenski, R.E. 1984. Two-step resistance by Escherichia coli B to bacteriophage T2. Genetics 107: 1-7.
38. Levin, B.R. & Bull, J.J. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2: 166-173.
39. Levy, S.B. & Marshall, B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10: S122-S129.
40. Li, Y.M., Xiang, Q., Zhang, Q.H., Huang, Y.D. & Su, Z.J. 2012. Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides 37: 207-215.
41. Lieberman, T.D., Michel, J.B., Aingaran, M., Potter-Bynoe, G., Roux, D., Davis, M.R. et al. 2011. Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat. Genet. 43: 1275-U148.
42. Marvig, R.L., Johansen, H.K., Molin, S. & Jelsbak, L. 2013. Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet. 9: e1003741.
43. Marvig, R.L., Madsen, L.M., Molin, S. & Johansen, H.K. 2014. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat. Genet. 47: 57-64.
44. Mcvay, C.S., Velasquez, M. & Fralick, J.A. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51: 1934-1938.
45. Merabishvili, M. 2014. Chapter 14.7.3.: Production of bacteriophages using bacterial suspension cultures for phage-therapy. In: Industrial Scale Suspension Culture of Living Cells (H.-P. Meyer & D. Schmidhalter, eds), pp. 537-543. Wiley-VCH Verlag GmbH &Co. KGaA, Weinheim, Germany.
46. Merabishvili, M., Pirnay, J.P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N. et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4: e4944.
47. Merabishvili, M., Verhelst, R., Glonti, T., Chanishvili, N., Krylov, V., Cuvelier, C., Tediashvili, M. & Vaneechoutte, M. 2007. Digitized fluorescent RFLP analysis (fRFLP) as a universal method for comparing genomes of culturable dsDNA viruses: application to bacteriophages. Res. Microbiol. 158: 572-581. [Correction added on 1 December after first online publication: Reference has been added].
48. Meyer, J.R., Dobias, D.T., Weitz, J.S., Barrick, J.E., Quick, R.T. & Lenski, R.E. 2012. Repeatability and contingency in the evolution of a key innovation in phage lambda. Science 335: 428-432.
49. Mizoguchi, K., Morita, M., Fischer, C.R., Yoichi, M., Tanji, Y. & Unno, H. 2003. Coevolution of bacteriophage PP01 and Escherichia coli O157: H7 in continuous culture. Appl. Environ. Microbiol. 69: 170-176.
50. Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L. & Debarbieux, L. 2011. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 6: e16963.
51. Mowat, E., Paterson, S., Fothergill, J.L., Wright, E.A., Ledson, M.J., Walshaw, M.J. et al. 2011. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 183: 1674-1679.
52. Ojeniyi, B., Birchandersen, A., Mansa, B., Rosdahl, V.T. & Hoiby, N. 1991. Morphology of Pseudomonas aeruginosa phages from the sputum of cystic-fibrosis patients and from the phage typing set - an electron-microscopy study. Apmis 99: 925-930.
53. Pirnay, J.P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M. et al. 2011. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28: 934-937.
54. Pleteneva, E., Shaburova, O. & Krylov, V. 2009. A formal scheme of adsorptional receptors in Pseudomonas aeruginosa and possibilities for its practical implementation. Russ. J. Genet. 45: 35-40. [Correction added on 1 December after first online publication: Reference has been added].
55. Rasko, D.A. & Sperandio, V. 2010. Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. Drug Discov. 9: 117-128.
56. Rau, M.H., Marvig, R.L., Ehrlich, G.D., Molin, S. & Jelsbak, L. 2012. Deletion and acquisition of genomic content during early stage adaptation of Pseudomonas aeruginosa to a human host environment. Environ. Microbiol. 14: 2200-2211.
57. Rose, T., Verbeken, G., De Vos, D., Merabishvili, M., Vaneechoutte, M., Lavigne, R. et al. 2014. Experimental phage therapy of burn wound infection: difficult first steps. Int. J. Burns Trauma 4: 66.
58. Savoia, D. 2012. Plant-derived antimicrobial compounds: alternatives to antibiotics. Future Microbiol. 7: 979-990.
59. Scanlan, P.D., Hall, A.R., Blackshields, G., Friman, V.P., Davis, M.R. Jr, Goldberg, J.B. et al. 2015. Coevolution with bacteriophages drives genome-wide host evolution and constrains the acquisition of abiotic-beneficial mutations. Mol. Biol. Evol. 32: 1425-1435.
60. Schmerer, M., Molineux, I.J. & Bull, J.J. 2014. Synergy as a rationale for phage therapy using phage cocktails. Peerj 2: e590.
61. Selezska, K., Kazmierczak, M., Musken, M., Garbe, J., Schobert, M., Haussler, S. et al. 2012. Pseudomonas aeruginosa population structure revisited under environmental focus: impact of water quality and phage pressure. Environ. Microbiol. 14: 1952-1967.
62. Sepulveda-Robles, O., Kameyama, L. & Guarneros, G. 2012. High diversity and novel species of Pseudomonas aeruginosa bacteriophages. Appl. Environ. Microbiol. 78: 4510-4515. [Correction added on 1 December after first online publication: Reference has been added].
63. Shanahan, F. 2010. Probiotics in perspective. Gastroenterology 139: 1808-1812.
64. Smith, H.W. & Huggins, M.B. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129: 2659-2675.
65. Tamaki, S., Sato, T. & Matsuhashi, M. 1971. Role of lipopolysaccharides in antibiotic resistance and bacteriophage adsorption of Escherichia coli K-12. J. Bacteriol. 105: 968-975.
66. Waddell, T.E., Franklin, K., Mazzocco, A. & Johnson, R.P. 2009. Preparation and characterization of anti-phage serum. In: Bacteriophages: Methods and Protocols, Vol. 1 (Isolation, Characterization, and Interactions) (M.R.J. Clokie & A.M. Kropinski, eds), pp. 287-292. Humana Press, New York, NY.
67. WHO 2014. Antimicrobial Resistance: Global Report on Surveillance. World Health Organization.
68. Willner, D., Haynes, M.R., Furlan, M., Hanson, N., Kirby, B., Lim, Y.W. et al. 2012a. Case studies of the spatial heterogeneity of DNA viruses in the cystic fibrosis lung. Am. J. Respir. Cell Mol. Biol. 46: 127-131.
69. Willner, D., Haynes, M.R., Furlan, M., Schmieder, R., Lim, Y.W., Rainey, P.B. et al. 2012b. Spatial distribution of microbial communities in the cystic fibrosis lung. ISME J. 6: 471-474.
70. Wright, A., Hawkins, C.H., Anggard, E.E. & Harper, D.R. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34: 349-357.
71. Yang, L., Jelsbak, L., Marvig, R.L., Damkiaer, S., Workman, C.T., Rau, M.H. et al. 2011. Evolutionary dynamics of bacteria in a human host environment. Proc. Natl. Acad. Sci. USA 108: 7481-7486.
72. Zhang, Q.G. & Buckling, A. 2011. Antagonistic coevolution limits population persistence of a virus in a thermally deteriorating environment. Ecol. Lett. 14: 282-288.